This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsInsider TradesNews and TrendsOwnershipShort Interest About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX) Get CPRX alerts:Sign Up Key Stats Today's Range$31.49▼$31.4950-Day Range$31.34▼$31.5152-Week Range$19.05▼$32.56VolumeN/AAverage Volume2.62 million shsMarket Capitalization$3.86 billionP/E Ratio18.10Dividend YieldN/APrice Target$32.00Consensus RatingModerate Buy Company Overview Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations. The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions. Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio. Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.AI Generated. May Contain Errors. Read More Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPRX Stock News HeadlinesItaly's Angelini Pharma completes $4.1 billion state-backed takeover of CatalystJuly 16, 2026 | reuters.comAngelini Pharma Completes Acquisition of Catalyst PharmaceuticalsJuly 16, 2026 | globenewswire.comA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Across the country, protests, lawsuits, and moratoria are targeting AI infrastructure projects. Whitney Tilson, former hedge fund manager and editor of Stansberry's Investment Advisory, says November 4 could bring this conflict to a head, with major implications for investors' portfolios.September 22 at 1:00 AM | Stansberry Research (Ad)Solaris Energy Infrastructure to join S&P SmallCap 600, replacing Catalyst PharmaJuly 10, 2026 | msn.comSanthera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®July 1, 2026 | finance.yahoo.comVamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical DosesJune 30, 2026 | globenewswire.comCatalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRXJune 24, 2026 | businesswire.comAngelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals StoryMay 20, 2026 | finance.yahoo.comSee More Headlines CPRX Stock Analysis - Frequently Asked Questions How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its quarterly earnings results on Thursday, November, 6th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.50 by $0.18. The biopharmaceutical company earned $148.39 million during the quarter, compared to analysts' expectations of $136.79 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 35.76% and a net margin of 37.08%. Read the conference call transcript. Is Catalyst Pharmaceuticals doing a stock buyback? Catalyst Pharmaceuticals' Board of Directors initiated a stock buyback plan on Wednesday, October 1st 2025, which authorizes the company to repurchase $200,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 8.3% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board of directors believes its shares are undervalued. Who are Catalyst Pharmaceuticals' major shareholders? Top institutional investors of Catalyst Pharmaceuticals include BlackRock Inc. (15.65%), Glazer Capital LLC (2.94%), HBK Investments L P (2.30%) and Jupiter Topco LLC (1.86%). Insiders that own company stock include Steve Miller, David S Tierney, Brian Elsbernd, Richard J Daly, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper. View institutional ownership trends. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/06/2025Today9/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CPRX's financial health is in the Green zone, according to TradeSmith. CPRX has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CPRX CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees80Year Founded2002Price Target and Rating Average Price Target for Catalyst Pharmaceuticals$32.00 High Price Target$33.00 Low Price Target$31.50 Potential Upside/Downside+1.6%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$1.74 Trailing P/E Ratio18.10 Forward P/E Ratio11.93 P/E Growth0.96Net Income$214.33 million Net Margins37.08% Pretax Margin49.66% Return on Equity35.76% Return on Assets31.31% Debt Debt-to-Equity RatioN/A Current Ratio7.10 Quick Ratio6.84 Sales & Book Value Annual Sales$596.96 million Price / Sales6.46 Cash Flow$2.92 per share Price / Cash Flow10.77 Book Value$7.76 per share Price / Book4.06Miscellaneous Outstanding Shares122,420,000Free Float109,688,000Market Cap$3.86 billion OptionableOptionable Beta0.74 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CPRX) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredChina's dominance in rare earth processing sparks new defense rulesOn January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adve...The Tomorrow Investor | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
